adrenaline demo süste-/infusioonilahus
demo s.a. - epinefriin (adrenaliin) - süste-/infusioonilahus - 1mg 1ml 1ml 50tk
lemoxol süste-/infusioonilahuse pulber
demo s.a. - tseftasidiim - süste-/infusioonilahuse pulber - 2000mg 1tk
lemoxol süste-/infusioonilahuse pulber
demo s.a. - tseftasidiim - süste-/infusioonilahuse pulber - 1000mg 1tk
adrenaline demo süste-/infusioonilahus
ideal trade links uab - epinefriin (adrenaliin) - süste-/infusioonilahus - 1mg 1ml 1ml 25tk; 1mg 1ml 1ml 50tk
linezolid accord infusioonilahus
accord healthcare b.v. - linesoliid - infusioonilahus - 2mg 1ml 300ml 10tk
oyavas
stada arzneimittel ag - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.
noradren süstelahus
demo s.a. - norepinefriin (noradrenaliin) - süstelahus - 1mg 1ml 4ml 50tk
poulvac pabac iv süsteemulsioon
zoetis belgium - pasteurella vaktsiin - süsteemulsioon - 500ml 1tk; 500ml 10tk
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
bravecto
intervet international b.v - fluralaner - nahaparasiidi-süsteemseks kasutamiseks, isoxazolines - dogs; cats - koerad:- ravi puugi ja kirbu infestatsioonid;preparaati võib kasutada osana ravi strateegia kontrolli kirbu allergia dermatiidi (fad). - raviks demodicosis põhjustatud demodex canis;- ravi sarcoptic mange (sarcoptes scabiei var. canis) nakatumise. - for reduction of the risk of infection with babesia canis canis via transmission by dermacentor reticulatus. [chewable tablets only]cats:- for the treatment of tick and flea infestations;the product can be used as part of a treatment strategy for the control of flea allergy dermatitis (fad). - raviks infestatsioonid koos kõrva lestad (otodectes cynotis).